𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia

✍ Scribed by Kloke, Otto ;Becher, Reinhard ;Niederle, Norbert

Publisher
Springer-Verlag
Year
1987
Weight
332 KB
Volume
55
Category
Article
ISSN
1432-0584

No coin nor oath required. For personal study only.

✦ Synopsis

A previously untreated patient with benign phase chronic myelogenous leukaemia (CML) was treated with recombinant Interferon alpha-2b. Haematological remission was induced for a total of twelve months. Thereafter, the patient developed resistance to Interferon alpha manifested by an increase in leucocyte counts despite dose escalation (up to 7x106 IU/day s.c.). Subsequent treatment with recombinant Interferon gamma failed to control myeloid proliferation. However, combined administration of both Interferon alpha and Interferon gamma resulted in a renewed haematological remission which lasted six months.

📜 SIMILAR VOLUMES

Results of triple therapy with interfero
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase
✍ Susan O'Brien; Francis Giles; Moshe Talpaz; Jorge Cortes; Mary Beth Rios; Jianqi 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

## Abstract ## BACKGROUND Before the discovery of imatinib mesylate, a Bcr‐Abl selective tyrosine kinase inhibitor, three agents, interferon‐alpha (IFN‐α), cytarabine (ara‐C), and homoharringtonine (HHT), had demonstrated activity against Philadelphia chromosome (Ph)‐positive chronic myelogenous l

Sequential therapy with recombinant inte
Sequential therapy with recombinant interferons gamma and alpha in patients with unfavorable prognosis of chronic myelocytic leukemia: Clinical responsiveness to recombinant ifn-α correlates with the degree of receptor down-regulation
✍ H. H. Bartsch; K. Pfizenmaier; A. Hanusch; P. Scheurich; U. Ücer; G. A. Nagel 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 710 KB

Natural and recombinant interferons (IFNs) have already demonstrated therapeutic efficacy, including cytogenetic re- missions, in patients with chronic myelocytic leukemia (CML). We investigated at the level of ligand-receptor interaction the question whether heterogeneity of receptor number or affi

Randomized trial of high-dose interferon
Randomized trial of high-dose interferon-α-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy
✍ Nami Mori; Michio Imamura; Yoshiiku Kawakami; Hiromi Saneto; Tomokazu Kawaoka; S 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 275 KB 👁 1 views

## Abstract The aim of this study was to compare the efficacy of high‐dose interferon (IFN)‐α‐2b with standard dose of IFN‐α‐2b in combination with ribavirin (RBV) for patients with chronic hepatitis C virus (HCV) infection, and to investigate the predictive factors associated with virological resp

Prevalence of hepatitis C virus genotype
Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin
✍ Kazuhiko Hayashi; Yoshiaki Katano; Teiji Kuzuya; Yoshihiko Tachi; Takashi Honda; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 2 views

## Abstract Hepatitis C virus (HCV) genotype 1a is rare in Japanese patients and the clinical characteristics of this genotype remain unclear. The interferon (IFN) sensitivity‐determining region (ISDR) and single‐nucleotide polymorphisms (SNPs) of interleukin‐28B (IL28B) among patients with HCV gen